New study checks cancer Drug's effect on common medications
NCT ID NCT07340190
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The goal is to gather information for safer drug use, not to treat the cancer itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGCandiolo, TO, 10060, Italy
-
Novartis Investigative Site
RECRUITINGPozuelo de Alarcón, Madrid, 28223, Spain
-
Novartis Investigative Site
RECRUITINGBarcelona, 08023, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28040, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28050, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug deliver a toxic payload directly to cancer cells?
- Cancer drug pralsetinib may change how the body processes other medications
- New drug combo shows promise for tough cancers
- Cancer drug pelabresib gets Long-Term safety check in extension trial
- New taxane drug RP-001 enters human trials for Hard-to-Treat cancers
- Cancer patients who respond to avelumab can keep taking it in this Follow-Up study